The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 03, 2015
Filed:
May. 20, 2013
Applicant:
Novartis Ag, Basel, CH;
Inventors:
Matthew Burger, Cambridge, MA (US);
Joseph E. Drumm, III, Walnut Creek, CA (US);
Gisele Nishiguchi, Arlington, MA (US);
Alice Rico, Castro Valley, CA (US);
Robert Lowell Simmons, San Francisco, CA (US);
Benjamin Taft, Oakland, CA (US);
Huw Tanner, San Francisco, CA (US);
Assignee:
NOVARTIS AG, Basel, CH;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 403/12 (2006.01); C07D 401/14 (2006.01); C07D 401/12 (2006.01); C07D 403/14 (2006.01); C07D 407/14 (2006.01); C07D 409/14 (2006.01); C07D 417/12 (2006.01); C07D 417/14 (2006.01); C07D 213/81 (2006.01); C07D 405/14 (2006.01); A61K 31/506 (2006.01); A61K 31/4439 (2006.01); A61K 31/444 (2006.01); A61K 31/4545 (2006.01); A61K 31/675 (2006.01); A61K 45/06 (2006.01); C07F 9/6558 (2006.01);
U.S. Cl.
CPC ...
A61K 31/506 (2013.01); A61K 31/444 (2013.01); A61K 31/4439 (2013.01); A61K 31/4545 (2013.01); A61K 31/675 (2013.01); A61K 45/06 (2013.01); C07D 213/81 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 403/12 (2013.01); C07D 403/14 (2013.01); C07D 405/14 (2013.01); C07D 407/14 (2013.01); C07D 409/14 (2013.01); C07D 417/12 (2013.01); C07D 417/14 (2013.01); C07F 9/65583 (2013.01);
Abstract
The present invention provides a compound of formula (A): as described herein, and pharmaceutically acceptable salts, enantiomers, rotamers, tautomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by PIM kinase using the compounds of Formula I, and pharmaceutical compositions comprising such compounds.